Literature DB >> 14514653

Mechanisms of suppression of neoplastic transformation in vitro by low doses of low LET radiation.

M C Pant1, X-Y Liao, Q Lu, S Molloi, E Elmore, J L Redpath.   

Abstract

Suppression of neoplastic transformation of HeLa x skin fibroblast human hybrid cells in vitro following low doses of low linear energy transfer radiation has been reported previously. The present study represents an exploration of two hypothesized mechanisms that may underlie this observed suppression. These are the up-regulation of reduced glutathione (GSH), a known antioxidant, and induction of DNA repair activity. The hybrid cells were found to have a high endogenous level of GSH and no induction following low doses of 60 kVp X-rays was observed. Buthionine sulfoximine (BSO), a GSH biosynthesis inhibitor, completely suppressed GSH levels in both unirradiated and irradiated cells. Furthermore, there was no significant impact of BSO-induced suppression of GSH on the neoplastic transformation frequency of either unirradiated or low dose irradiated cells indicating that glutathione levels play no role in the low dose suppression of transformation frequency. To assess the possible role of DNA repair in the low dose suppression of transformation the effect of 3-aminobenzamide (3-AB), a poly-ADP-ribose polymerase (PARP) inhibitor was examined. In these experiments, there was no significant effect of 3-AB on the transformation frequency at a dose of Cs-137 gamma rays of 0.5 cGy, however, at a dose of 5 cGy there was a significant increase (P < 0.05) in the transformation frequency in the presence of 3-AB. These findings suggest that the influence of DNA repair on the low dose suppression of transformation is significant at a dose of 5 cGy, but not at the lower dose of 0.5 cGy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14514653     DOI: 10.1093/carcin/bgg172

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  11 in total

1.  A perspective on the scientific, philosophical, and policy dimensions of hormesis.

Authors:  George R Hoffmann
Journal:  Dose Response       Date:  2009-01-19       Impact factor: 2.658

2.  Suppression of neoplastic transformation in vitro by low doses of low LET radiation.

Authors:  J Leslie Redpath
Journal:  Dose Response       Date:  2006-11-27       Impact factor: 2.658

3.  Non-problematic risks from low-dose radiation-induced DNA damage clusters.

Authors:  Daniel P Hayes
Journal:  Dose Response       Date:  2008-01-16       Impact factor: 2.658

4.  Protective bystander effects simulated with the state-vector model.

Authors:  Helmut Schöllnberger; Peter M Eckl
Journal:  Dose Response       Date:  2007-06-26       Impact factor: 2.658

5.  Nonlinear response for neoplastic transformation following low doses of low let radiation.

Authors:  J Leslie Redpath
Journal:  Nonlinearity Biol Toxicol Med       Date:  2005-01

6.  Computational modeling of cellular effects post-irradiation with low- and high-let particles and different absorbed doses.

Authors:  Adriana Alexandre S Tavares; João Manuel R S Tavares
Journal:  Dose Response       Date:  2012-03-19       Impact factor: 2.658

7.  Detrimental and protective bystander effects: a model approach.

Authors:  H Schöllnberger; R E J Mitchel; J L Redpath; D J Crawford-Brown; W Hofmann
Journal:  Radiat Res       Date:  2007-11       Impact factor: 2.841

8.  Low-dose radiation-induced protective process and implications for risk assessment, cancer prevention, and cancer therapy.

Authors:  B R Scott
Journal:  Dose Response       Date:  2007-06-04       Impact factor: 2.658

9.  Radiation-induced neoplastic transformation in vitro, hormesis and risk assessment.

Authors:  J Leslie Redpath; Eugene Elmore
Journal:  Dose Response       Date:  2006-12-06       Impact factor: 2.658

10.  An examination of radiation hormesis mechanisms using a multistage carcinogenesis model.

Authors:  H Schöllnberger; R D Stewart; R E J Mitchel; W Hofmann
Journal:  Nonlinearity Biol Toxicol Med       Date:  2004-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.